Welcome to our dedicated page for International Stem Cell news (Ticker: ISCO), a resource for investors and traders seeking the latest updates and insights on International Stem Cell stock.
International Stem Cell Corporation (ISCO) is a California-based clinical stage biotechnology company focused on human parthenogenetic stem cells (hpSCs), therapeutic development and cell-based commercial products. Its news flow, as reflected in public releases, centers on progress in stem cell-based therapies, financial performance and the activities of its subsidiaries Lifeline Cell Technology and Lifeline Skin Care.
Investors and observers following ISCO news can expect updates on its lead neural stem cell candidate ISC-hpNSC®, which the company is evaluating in a Phase 1 clinical trial for Parkinson’s disease. News items describe safety, tolerability and preliminary efficacy data from this dose-escalation study, including longer-term follow-up of patients after intracranial transplantation and assessments using Parkinson’s disease-specific scales and imaging.
ISCO also issues regular financial updates, reporting product sales, operating income from its revenue-generating subsidiaries, research and development expenses and net loss. These releases highlight trends in revenues from specialized cells and growth media for therapeutic research, as well as stem cell-based skin care products, providing context on how the commercial units support the broader stem cell platform.
Additional disclosures may cover governance and capital structure topics reported in SEC filings, such as stockholder meeting outcomes and related party financing arrangements. For readers tracking ISCO, this news page offers a centralized view of clinical trial milestones, preclinical findings, subsidiary performance and corporate developments related to the company’s hpSC-based technologies and OTC-traded stock.
International Stem Cell (ISCO) has released its financial results for Q4 and full-year 2024, showing significant improvements in key metrics. Revenue grew 17% to $9.09 million in 2024, up from $7.79 million in 2023. The company's subsidiaries, Lifeline Cell Technology and Lifeline Skin Care, reported a 29% increase in combined operating income to $2.39 million, compared to $1.85 million in 2023.
Notably, ISCO substantially reduced its loss from operations by 90% to $68,000 in 2024, down from $663,000 in 2023. The company continues to advance its ISC-hpNSC® program, with promising interim results in its Phase 1 clinical trial.
International Stem Cell Corporation (ISCO) has reported financial results for Q1 2022, showcasing significant growth. Consolidated revenue reached $2.02 million, marking a 22% increase from $1.66 million in Q1 2021. The company reported a combined operating income of $648,000, which is up 164% from $245,000 year-over-year. Notably, ISCO's net loss shrank to $9,000, a substantial improvement from a net loss of $599,000 in the same quarter of the previous year. CEO Andrey Semechkin highlighted the positive trajectory of business units and the progress of their Phase 1 clinical trial.
International Stem Cell Corporation (ISCO) announced its 2021 financial results and provided updates on its phase 1 clinical trial for ISC-hpNSC® in treating Parkinson's disease. The company reported a slight revenue increase to $7.18 million, with a notable 127% rise in operating income to $1.35 million. The net loss significantly decreased to $899,000. In clinical outcomes, patients in the trial demonstrated a 47% reduction in % OFF-Time at 12 months and a 43% improvement in quality of life, validating the treatment's safety and efficacy over 48 months.
International Stem Cell Corporation (OTCQB:ISCO) announced the successful completion of its Phase 1 clinical trial for ISC-hpNSC® in treating Parkinson's disease. The trial evaluated the safety and tolerability of various doses over 24 months, revealing no serious adverse effects. Patients showed significant improvements, including a 55% reduction in % OFF-Time and a 45% improvement in quality of life. The company is optimistic about further research to determine the most effective dosage for enhanced efficacy.